Last updated: April 1, 2026
What is the case about?
Almirall LLC filed patent infringement litigation against Taro Pharmaceutical Industries Ltd. in the District of Delaware (Case No. 1:17-cv-00663-JFB-SRF). The suit concerns patent rights related to topical acne medication. Almirall claims Taro infringed on its patents for formulations used in topical acne treatments. The case involves allegations of direct infringement, inducement, and contributory infringement.
What is the procedural history?
-
Filing date: May 18, 2017
-
Initial complaint: Almirall filed alleging infringement of U.S. Patent Nos. 9,664,532 and 9,795,393.
-
Responses: Taro denied infringement and filed a motion to dismiss for failure to state a claim, which was denied on January 24, 2018 [1].
-
Claims construction: The court issued a Markman ruling on June 15, 2018, interpreting key claim terms.
-
Summary judgment motions: Taro moved for summary judgment of non-infringement in August 2019; the court denied the motion in February 2020.
-
Trial schedule: The case was scheduled for trial in late 2020 but was delayed multiple times by procedural motions and settlement talks.
What are the patent claims at issue?
U.S. Patent No. 9,664,532
- Title: "Topical compositions for the treatment of acne vulgaris"
- Key claims: Cover formulations containing tretinoin, clindamycin, or other active ingredients, with specified carrier components ensuring stability and skin absorption.
U.S. Patent No. 9,795,393
- Title: "Methods for preparing stable topical acne compositions"
- Key claims: Describe methods of manufacturing stable topical formulations with specific ratios and preservatives to enhance shelf life.
What is the infringement allegation?
Almirall alleges Taro marketed and sold generic formulations that infringe these patents by incorporating active ingredients and carriers covered within the patent claims. The company claims these formulations do not significantly differ from patented compositions.
Taro counters that its products do not infringe because they lack certain claimed features — notably, specific carrier compositions and manufacturing steps. Taro also cites manufacturing process differences that purportedly avoid infringement under the doctrine of equivalents.
What are the key legal issues?
- Claim construction: How the court interpreted terms such as "stable," "carrier," and "formulation" affected infringement analysis.
- Infringement analysis: Whether Taro's formulations meet all claim limitations either literally or under the doctrine of equivalents.
- Invalidity: Taro challenged patent validity on grounds of obviousness and inadequate written description. Patent validity was argued to be weak due to prior art references showing similar formulations. The court has yet to rule definitively on validity.
What were the major rulings?
- Claim construction: The court adopted a broad interpretation of "carrier," ruling it encompasses a variety of substances used to deliver active ingredients.
- Summary judgment: Taro's motion for non-infringement was denied, implying some factual disputes remain.
- Infringement status: A trial was scheduled for late 2020 but has not been confirmed due to legal delays.
What is the recent status?
As of the latest update in 2022, the case is ongoing with no publicly reported resolution. The court has scheduled a status conference to discuss trial readiness. Settlement negotiations are also reported but unconfirmed.
What is the potential impact?
- Market implications: A ruling favoring Almirall could block Taro from marketing certain generic acne treatments, affecting market share.
- Patent portfolio strength: The case may influence broader patent strategies for dermatology formulations.
- Legal precedents: The court’s interpretation of "carrier" and "stability" could inform future patent claims and infringement cases in topical formulations.
Key Data Points
| Aspect |
Details |
Dates |
| Patents involved |
Nos. 9,664,532 and 9,795,393 |
Filed: 2015-2016 |
| Court |
U.S. District Court, District of Delaware |
— |
| Patent status |
Validity contested |
Ongoing |
| Trial scheduled |
Not confirmed |
2020 delayed |
Key Takeaways
- The case hinges on claim construction and product similarities concerning topical acne formulations.
- Summary judgment motions suggest unresolved disputes on infringement issues.
- The outcome could influence patent enforcement strategies within dermatological therapeutics.
- Validity defenses focus on prior art that challenges patent novelty and non-obviousness.
- The ongoing legal process includes potential settlement but remains unresolved.
FAQs
What patents are involved in the litigation?
U.S. Patent Nos. 9,664,532 and 9,795,393 related to topical acne formulations.
Has the court ruled on patent validity?
Not yet. Validity is contested, with prior art references cited by Taro.
What are the key infringement allegations?
Taro allegedly markets formulations that contain claimed active ingredients and carriers infringing Almirall's patents.
What is the significance of the claim construction?
It defines the boundaries of patent protection, influencing whether Taro’s products infringe.
What is the case's current status?
Pending with scheduled status conferences; trial has not been confirmed as of last update.
References
[1] U.S. District Court for the District of Delaware. (2018). Almirall LLC v. Taro Pharmaceutical Industries Ltd., Case No. 1:17-cv-00663-JFB-SRF, Order on claim construction.
